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Eyal C. Attar, Yi-Bin Chen, Richard L. Haspel, Deborah Liney, John Koreth, Vincent Ho,
Edwin P. Alyea, Robert J. Soiffer, Thomas R. Spitzer, Joseph H. AntinDouble umbilical cord blood transplantation (UCBT) with a reduced-intensity conditioning regimen is an ef-
fective strategy for adult patients without a matched donor. The risk of second malignancies in these patients
has not yet beenestablished, however. In the present study, 98 adultswith a hematologicmalignancyunderwent
doubleUCBT. Seventy patients received a reduced-intensity conditioning regimen of fludarabine 30mg/m2/day
for 6 days, melphalan 100mg/m2/day for 1 day, and rabbit antithymocyte globulin 1.5 mg/kg/day for 4 days, and
28 patients received amyeloablative total body radiation–containing conditioning regimen. Sixty-three patients
received sirolimus-based graft-versus-host disease (GVHD) prophylaxis, and 35 patients received non–siroli-
mus-based GVHD prophylaxis. The median patient age was 48 years (range, 19-67 years). Eighteen patients
developed a second malignancy at a median of 134 days after transplantation. Sixteen patients had lymphoma,
and 2 patients hadmyelodysplasic syndrome/myeloproliferative disorder (MDS/MPD). Sixteen of these second
malignancies (both cases ofMDS/MPDand14of the lymphomas)were donor-derived; the origins of the others
were not determined. GVHD prophylaxis, HLA matching, primary disease, age, total nucleated cell dose, and
CD341 cell dosewere not associated with a higher rate of secondmalignancy. Secondmyelogenousmalignan-
cies of donororigin occur after double UCBT, suggesting that a search for donor origin should be performed in
all patients with suspected relapse.
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Umbilical cord blood is an alternative stem cell
source for patients without a matched related or unre-
lated donor. A projected disease-free survival (DFS) of
approximately 30%-60% has been observed in adults
receiving umbilical cord blood (UCB)–derived hemato-
poietic stem cell transplantation (HSCT) using either
a single cord blood product [1-4] or 2 cord blood
products [5-7]. Most of these transplantations use
donors mismatched at multiple HLA antigens,epartment of Medicine, Massachusetts General Hospital
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T cells, which are present in small numbers. Thus,
there is an inherent risk of posttransplantation
lymphoproliferative disorder (PTLD). Stimulation of
limited numbers of stem and progenitor cells may
increase the risk of myelodysplasia (myelodysplasic
syndrome [MDS]/myeloproliferative disorder [MPD])
and acute myelogenous leukemia (AML) [8]. Finally,
mutations that are associated with the later develop-
ment of leukemia have been identified in postpartum
UCB [9].
Second malignancies may be of recipient or, more
rarely, donor origin [10-13]. Recent analyses of the risk
of second malignancy after allogeneic HSCT suggest
an incidence of 6%-12% [14,15]. The risk of solid
tumors does not appear to plateau, however. A
retrospective study of 18,000 patients reported to
the Center for International Blood and Marrow
Transplant Research (CIBMTR) indicates a 1%
incidence of PTLD, with 82% of cases occurring
during the first year after transplantation [14]. Known
risk factors for PTLD include Epstein-Barr virus
(EBV) infection, HLA mismatch, use of antithymocyte1025
1026 Biol Blood Marrow Transplant 16:1025-1031, 2010K. K. Ballen et al.globulin (ATG), T cell depletion, and chronic
graft-versus-host disease (cGVHD). The incidence
of PTLD after reduced-intensity (RIC) double cord
blood transplantation ranges from 3% to as high as
21% when ATG is used in the conditioning regimen
[16].
Second myeloid malignancies are rare after alloge-
neic HSCT using living donor Bone marrow (BM) or
peripheral blood stem cells (PBSCs). There have been
individual case reports of secondary myeloid malig-
nancies of donor origin after allogeneic HSCT, with
an estimated incidence of\0.25% [17-23].
Because relapse of the primary disease may be
difficult to distinguish from donor-derived secondary
leukemia unless cytogenetic or molecular techniques
are used, the actual incidence of donor-derived second
malignancies may be underreported. In this study, we
explored the incidence and outcomes of secondary
hematologic malignancies in 98 patients who underwent
double UCB HSCT.METHODS
Patients
Consecutive patients with a hematologic malig-
nancy undergoing double UCB transplantation
(UCBT) were analyzed retrospectively. Patients were
eligible for RIC double UCB HSCT if they had no 5/
6 or 6/6 HLA-A, -B, or -DR allele-level matched related
donor or no 6/6 HLA-A, -B, or -DR allele-level
matched unrelated donor. Patients with acute leukemia
were eligible if they were in first remission with high-
risk cytogenetics or in second or subsequent remission.
Patients with refractory leukemia were not eligible. Pa-
tients with chemotherapy-sensitive relapsed lymphoma
were eligible, as were patients with MDS, chronic mye-
logenous leukemia (CML) refractory to tyrosine kinase
inhibitors, or chronic lymphocytic leukemia (CLL) that
progressed after at least 2 regimens.Conditioning Regimen and GVHD Prophylaxis
All patients in the RIC arm received a regimen of
fludarabine (Flu) 30 mg/m2/day on days -8 through -3
(total dose 180 mg/m2), melphalan 100 mg/m2/day on
day -2, and rabbit ATG (Genzyme, Cambridge, MA)
1.5 mg/kg/day on days 27, 25, 23, and 21 (total
dose, 6.0 mg/kg). Patients under the age of 45 years
with no comorbid conditions were eligible to receive
a myeloablative (MA) conditioning regimen consisting
of Flu 25 mg/m2/day on days 26, 25, and 24 (total
dose, 75 mg/m2); cyclophosphamide 1800 mg/m2/day
on days26 and25 (total dose, 3600 mg/m2); and total
body irradiation 14 Gy in 7 fractions on days 23, 22,
21, and 0. Four patients also received ATG in addition
to the foregoing regimen. Sixty-three patients receivedsirolimus-based GVHD prophylaxis with sirolimus
(target trough serum concentration, 3-12 ng/mL) and
tacrolimus (target trough serum concentration, 5-10
ng/mL) [24]. GVHD prophylaxis was tapered after
day 1100 if there was no evidence of acute GVHD
(aGVHD). Thirty-five patients received GVHD pro-
phylaxis with either tacrolimus as above or cyclosporine
(CsA) in continuous i.v. infusion starting on day -3 and
mycophenolate mofetil (MMF) 15 mg/kg twice daily
starting on day 0, with tapering of MMF after day
160 and of CsA after day1100 if there was no evidence
of aGVHD [6]. Eleven patients received parathyroid
hormone 100 mg/day for 28 days after transplantation
on a concomitant trial. The protocols were reviewed
and approved by the Dana-Farber/Harvard Cancer
Center’s Institutional Review Board, and written
informed consent was obtained from all patients.
Cord Unit Selection
CB units were obtained from national and interna-
tional registries. Each CB unit had to meet a minimum
cell dose requirement of .1.5  107 nucleated cells
(NCs)/kg prefreeze for each individual unit and 3.7 
107 NCs/kg prefreeze for both units combined. CB
units had to be at least a 4/6 HLA-A, -B, and -DR
allele-level match with the patient and with one another
other. HLA-C typing was performed on the CB units,
but was not used in the matching strategy. CB units
were washed with dextran and albumin and infused
sequentially 1-6 hours apart [25].
Second Malignancies
All patients are followed for survival, relapse, and
second malignancies. When possible, the donor origin
of the second malignancy was assessed by routine
cytogenetics or chimerism studies. Chimerism assays
of peripheral blood buffy coat isolates were performed
by short tandem repeat analysis using a multiplex kit
with primers for 10 different loci (Profiler Plus;
Applied Biosystems, Foster City, CA), as described pre-
viously [26]. Patients were monitored for EBV by DNA
analysis every other week, and rituximab therapy was
administered in patients with a sustained level .1000
copies/ml.
Statistical Analysis
The times to the outcome events were measured
from day 0 of CB infusion. Overall survival (OS) was
measured until the date of death or was censored at
the last follow-up for patients who were still alive.
DFS was measured until the earlier date of relapse or
death, and was censored at the last follow-up for pa-
tients who were alive and free of relapse. OS and
DFS were estimated using the Kaplan-Meier method.
Treatment-related mortality (TRM) was based on the
cumulative incidence estimated in the presence of
Biol Blood Marrow Transplant 16:1025-1031, 2010 1027Second Malignancy after UCBTrelapse as a competing risk [27]. The absolute risk of
second malignancy was based on the cumulative inci-
dence estimated by considering death as a competing
risk using the method of Gray [27]. Patients who had
not developed a second malignancy or died were cen-
sored at their last follow-up. To adjust for confound-
ing, the associations between patient or CB unit
characteristics and incidence of second malignancy
were analyzed in a multivariate model. In particular,
competing-risks regression using the method of Fine
and Gray [28] was used to assess the joint effects of
age, primary disease, conditioning regimen, GVHD
prophylaxis, HLA matching, NC dose, and CD341
dose. The relative risk of developing a second malig-
nancy was based on the estimated hazard ratio (HR),
with the 95% confidence interval (CI) calculated by
taking exponents of the 95% CI for the regression co-
efficient. SAS version 9.1 (SAS Institute, Cary, NC)
was used to perform the general computations, and
the cmprsk package in R version 2.5.1 was used in
competing-risks analyses. All P values are based on
2-sided hypothesis tests. Given the modest sample
size available for a multivariate model with several
covariates, a P value\.20 was considered to suggest
a trend within a hypothesis-generating framework.RESULTS
Patient Characteristics
Table 1 summarizes characteristics of the 98
patients in the study group. The median patient age
was 48 years (range, 19-67 years). The majority of the
patients had either acute leukemia (40 patients) or
relapsed non-Hodgkin lymphoma (NHL; 19 patients);
80% were Caucasian. In terms of risk, 20% of the
patients with leukemia were considered standard risk,
and 80% were considered high risk. The median
follow-up was 29 months (range, 6-69 months), with
43 patients alive as of September, 2009. In terms of con-
ditioning, 29% of the patients received an MA regimen,
and 71% received a RIC regimen. Patients with MDS,
CML, and aplastic anemia were more common in the
MA group (56% vs 21%), whereas patients with lym-
phoma were more often treated with the RIC regimen
(28% vs 3%).CB Unit Characteristics
Table 2 summarizes characteristics of the CB units
infused. The median NC dose infused for the com-
bined CB units was 4.4  107 NCs/kg (range, 1.3-8.5
 107 NCs/kg), and the median CD341 dose infused
for the combined CB units was 2.4  105 CD341
cells/kg (range, 0.3-11.5). Seventy-six percent of the
patients received two 4/6 HLA-A, -B, and -DR
allele-level matched CB units; 14% received one 4/6and one 5/6 matched cord blood unit; and the remain-
ing 8% received two 5/6 matched cord blood units.
No patient received a 6/6 matched cord blood unit.
Second Malignancies
Eighteen patients (18%) developed a second ma-
lignancy, corresponding to an actuarial rate of 19%
at 26 months after transplantation. The median time
to development of a second malignancy was 134 days
(range, 39 days to 26 months). Thirteen of these pa-
tients died, all from the second malignancy. Table 3
presents characteristics of the patients with a second
malignancy. Eleven patients received parathyroid
hormone after transplantation; one of these patients
developed a second malignancy. No solid tumors
were observed in this population, with a median
follow-up after transplantation of 29 months.
EBV PTLD
Sixteen patients had EBV PTLD, 14 with donor-
derived disease as measured by chimerism assay and
2 with disease of undetermined origin. In 1 patient,
the BM demonstrated chimerism from one CB unit,
and the lung tissue with PTLD exhibited chimerism
from the other cord blood unit. Posttransplantation
lymphoma developed a median of 117 days after trans-
plantation (range, 39-368 days). The primary diseases
were Hodgkin lymphoma (n5 3), NHL (n5 3), CLL
(n5 1), CML (n 5 1), aplastic anemia (n 5 2), MDS/
MPS (n5 3), and AML (n5 3). The median maximum
EBV viral load was 9500 copies/mL (range, 240-5.4
million copies/mL). Thirteen patients had widespread
organ involvement at the time of diagnosis, and 2 pa-
tients were treated for an elevated EBV viral load.
Twelve patients were treated with rituximab; 3 pa-
tients received rituximab and CHOP (cyclophospha-
mide, adriamycin, vincristine, and prednisone). Eight
patients died with fulminant disease within 2 weeks
of diagnosis. Three patients also received EBV-
specific cytotoxic T lymphocytes after failure of ritux-
imab; 1 of these patients is alive in sustained remission.
EBV PTLD was fatal in 11 patients.
Overall, 5 patients were alive and in remission
a median of 12 months after the diagnosis of PTLD.
These surviving patients developed PTLD at a median
of 5 months posttransplantation (range, 4-12 months),
similar to the general cohort of PTLD patients. The
median EBV viral load in these 5 patients was 7000
copies/mL (range, 603-340,000 copies/mL). All
5 patients received rituximab; 1 patient also received
R-CHOP, and 1 patient also received EBV-specific
cytotoxic T lymphocytes.
Patients were monitored for the development of
EBV viremia every other week up to day 1180 and
as clinically indicated after day 1180. An additional
12 patients developed EBV viremia, but did not
Table 1. Patient Characteristics
Age, years, median (range) 48 (19-67)
Male sex, % 57%
Malignancy, n (%)
AML 33 (34%)
NHL 19 (19%)
Hodgkin lymphoma 8 (8%)
Aplastic anemia 7 (7%)
MDS 12 (12%)
CLL/PLL 6 (6%)
Acute lymphoblastic leukemia 6 (6%)
CML 4 (4%)
Other 3(3%)
Transplantation risk, n (%)*
Standard 18 (20%)
High 70 (80%)
Conditioning regimen, n (%)
Reduced-intensity 70 (71%)
Myeloablative 28 (29%)
GVHD prophylaxis, n (%)
Sirolimus-based 63 (64%)
Non–sirolimus-based 35 (36%)
AML indicates acute myelogenous leukemia; NHL, non-hodgkin lym-
phoma; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leu-
kemia; PLL, prolymphocytic leukemia; CML, chronic myelogenous
leukemia; GVHD, graft-versus-host disease.
*Standard risk: AML/acute lymphoblastic leukemia in first complete
response, MDS with refractory anemia/refractory anemia with ringed
sideroblasts, CML in chronic phase1; high risk: all others, excluding
aplastic anemia and lymphoma.
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viral load of 500 copies/mL (range, 200-3300 copies/
mL). EBV viremia occurred at a median of 89 days af-
ter transplantation (range, 22-1460 days). Two of
these patients received rituximab as part of treatment
for relapsed disease.
Second Malignancy with MDS/MPD
Two patients developed MDS/MPD and died.
The actuarial rate of donor-derived myelogenous dis-
ease was 3%. Both of these patients had received RIC
with Flu, melphalan, and rabbit ATG. One of these
patients was a male who underwent HSCT for NHL
21 months after undergoing double CBT. He had
been slow to engraft and was receiving filgrastim. He
developed myelodysplasia, with BM showing 11%
myeloblasts, consistent with refractory anemia with
excess blasts, and 100% XX cytogenetics. He was
treated with 5 azacytidine without improvement.
The other patient, a female, experienced confirmed
donor-derived secondary myelodysplasia at 26 monthsTable 2. Cord Blood Characteristics
Infused cell dose, combined cord
blood units, median (range)
NCs/kg 4.4  107 (1.3-8.8)
CD 34+ cells/kg 2.4  105 (0.3-11.5)
HLA match (-A, -B, -DRB1), n (%)
4/6, 4/6 76 (78%)
4/6, 5/6 14 (14%)
5/6, 5/6 8 (8%)
5/6, 6/6 0
6/6, 6/6 0after HSCT for AML. She had hypercellular BM with
left-shifted myelogenous cells, erythroid dysplasia, and
100% XY cytogenetics, and was treated with steroids
and splenectomy without improvement.
These cases of donor-derived second myelogenous
malignancies were reported to the CB banks that
provided the CB units. In the first case, follow-up de-
termined that both CB donors were healthy. No infor-
mation was available for the second cases.
Predictors of Second Malignancies
Age, primary disease, conditioning regimen,
GVHD prophylaxis, HLA matching, NC dose, and
CD341 cell dose were studied in a multivariate analysis
to identify independent predictors of a second malig-
nancy (Table 4). RIC was associated with a trend
toward an increased incidence of second malignancy
compared with MA conditioning (24% vs 7%), but
this effect was confounded with the effect of ATG.
ATG was administered to all patients receiving a RIC
regimen, as opposed to only 4 patients (14%) receiving
a MA regimen. A RIC regimen with ATG was associ-
ated with a trend toward an increased risk of developing
a second malignancy, but the effect was not significant
(P 5 .23). Patients with primary Hodgkin lymphoma
had a 38% incidence of second malignancy, higher
than the 18% associated with other diseases, but this ef-
fect was not significant (P 5 .06). Older age, GVHD
prophylaxis, HLA matching, total NC dose, and
CD341 cell dose were not associated with an increased
incidence of second malignancy. Both of the patients
with donor-derived MDS/MPD had received ATG,
but risk factors for MDS/MPD could not be deter-
mined because of the small number of patients.
Survival
As reported previously, the RIC CsA/MMF group
had 1-year overall and disease-free survivals of 71% and
62%, respectively [6]. Two-year overall and disease-
free survival was 57% and 57%. The reduced-
intensity group with either CsA/MMF or sirolimus/
tacrolimus GVHD prophylaxis had overall and
disease-free survivals of 63% and 51% respectively at
1 year and 48% and 33% at 2 years. In the MA group,
OS and DFS were 35% and 35% at 1 and 2 years,
respectively. For the entire cohort, 100-day TRM
was 26%, with infection the leading cause of death.
The majority of deaths from second malignancy
occurred after 100 days, and thus these patients were
not included in the 100-day TRM. With a median
follow-up of 29 months for the 43 patients still alive,
the OS and DFS for the entire cohort were 55% and
47% at 1 year and 44% and 32% at 2 years (Figures 1
and 2), respectively. Twenty-four patients experienced
disease relapse; in 10 of these patients, cytogenics
determined the relapse to be of recipient origin.
Table 3. Second Malignancies
Primary Disease
Type of Second
Malignancy Derivation Outcome
AML MDS/MPD Donor Fatal
Hodgkin lymphoma PTLD Donor Fatal
NHL MDS/MPD Donor Fatal
Hodgkin lymphoma PTLD Unknown Fatal
CLL PTLD Donor Fatal
MDS PTLD Donor Fatal
AML PTLD Donor Fatal
MDS PTLD Donor Alive, in CR
NHL PTLD Donor Fatal
Hodgkin lymphoma PTLD Donor Fatal
AML PTLD Donor Fatal
AML PTLD Donor Alive, in CR
NHL PTLD Donor Fatal
NHL PTLD Donor Fatal
MDS PTLD Donor Fatal
Aplastic anemia PTLD Donor Alive, in CR
Aplastic anemia PTLD Donor Alive, in CR
CML PTLD Unknown Alive, in CR
CR indicates complete response; AML, acute myelogenous leukemia;
NHL, non-hodgkin lymphoma; CLL, chronic lymphocytic leukemia;
MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia.
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Approximately 10,000 UCB HSCTs have been per-
formed worldwide, the majority for hematologic malig-
nancies [1-4]. Recently, double UCB HSCT has been
used in adult patients to shorten engraftment times and
reduce the risk of infection [5-7,29]. Although second
malignancies have been reported after double CB
HSCT, the magnitude of the risk is uncertain. We
report a high incidence (19%) of second malignancies,
including a surprising 3% incidence of donor-derived
myeloid malignancies.
Similar to the Minnesota group [16], we found
a high incidence of PTLD in our patients who under-
went double CB HSCT. Our incidence of PTLD is
higher than that reported in some double CBT series,
but is comparable to the incidence reported by the
Minnesota group in patients undergoing reduced-
intensity HSCT with ATG [16]. Brunstein et al.Table 4. Predictors for Second Malignancies
Patient or Cord
Unit Characteristic Risk Group
Age >50 years
#50 years
Primary disease Hodgkin lymphoma
Other malignancies
Conditioning regimen Reduced-intensity
Myeloablative
GVHD prophylaxis Sirolimus-based
Other agents
HLA matching 4/6, 5/6 or 5/6, 5/6, 4/6, 4/6
NC dose infused >4.4  107/kg
#4.4  107/kg
CD34+ cell dose infused #2.4  105/kg
>2.4  105/kg
GVHD indicates graft-versus-host disease.reported a 3% incidence of PTLD in patients
who received an MA conditioning regimen
containing ATG (3% with ATG vs 0 with no ATG);
however, the incidence of PTLD was significantly
higher in patients who received a RI regimen with
ATG (21%, compared with 2% with no ATG). The
increased incidence of PTLD after cord blood
HSCT may be related to the absence of EBV-
specific memory T cells in CB grafts [30]. The reason
for the increase with reduced-intensity conditioning is
not completely understood but may be related to the
number of residual recipient B cells remaining after
conditioning [31]. Although weekly or biweekly EBV
monitoring may help identify early viral reactivation,
the PTLD occurring after CB HSCT appears to be
more aggressive than that occurring after solid organ
transplantation, with rapid progression to multiorgan
involvement and lack of responsiveness to rituximab
[31,32]. However, the risk of death in our patients
who developed PTLD (69%) was similar to that
reported in other stem cell transplantation series; for
example, a German group reported 82% mortality in
their HSCT patients who developed PTLD [33,34].
PTLD after HSCT of all sources has a poorer
prognosis than PTLD after solid organ
transplantation.
Previous analyses of conventional HSCT identified
T cell depletion, HLA disparity, GVHD, and the use of
ATG as risk factors for PTLD [14,33,34]. After the first
year, however, the major risk factor was cGVHD [14].
In our cord blood cohort, no variables were found to be
statistically significant, although reduced-intensity
conditioning with the use of ATG was associated
with a trend toward increased risk of a second malig-
nancy. Intensive monitoring, decreased ATG doses,
prompt administration of EBV-specific cytotoxic T
cells, and the addition of rituximab to the conditioning
might decrease the incidence of PTLD [35-37]. For
example, an Italian group administered a single dose
of rituximab on day 15 after CB HSCT [38].Cumulative Incidence HR (95% CI) P value
26% 1.8 (0.8-4.8) .270
14%
38% 2.8 (0.6-4.8) .064
18%
24% 2.5 (0.6-10.6) .230
7%
20% 1.1 (0.5-2.9) .800
18%
30% 0.9 (0.3-2.6) .350
16%
21% 1.5 (0.6-3.9) .350
17%
21% 1.5 (0.6-3.6) .380
15%
Overall Survival (months)
0 12 24 36 48 60
0%
20%
40%
60%
80%
100%
Figure 1. Overall survival for the entire cohort from the time of
transplantation.
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follow-up was short, a median of 30 months after
HSCT. An increased incidence of squamous cell can-
cer has been reported in older patients with cGVHD,
some of which are of donor origin [39-41].
The incidence of donor-derived MDS/MPD in this
study (3%) is higher than that reported in the literature
after adult HSCT with donor bone marrow or PBSCs
(\0.25%) [17-23]. Our incidence is also higher than
that reported in other CBT series; however, donor-
derived myeloid malignancy may be underreported, be-
cause donor-derived AML is difficult to distinguish
from relapsed leukemia in the absence of cytogenetic
or chimerism data [4,5,7]. Because donor derivation
by chimerism or cytogenetics is not done routinely
after HSCT, the true incidence after CB or standard
transplantation is unknown. The biology underlying
the development of a second malignancy is unclear.
Both of our patients with donor-derived MDS/MPD
had received an RIC regimen containing ATG, but
the small number of patients precludes identification
of specific risk factors.
The possibility exists that compared with adult
blood, cord blood may be more likely to containDisease-Free Survival (months)
0 12 24 36 48 60
0%
20%
40%
60%
80%
100%
Figure 2. Disease-free survival for the entire cohort from the time of
transplantation.preleukemic cells and contribute to a first ‘‘hit’’ in
the ‘‘two-hit’’ development of a second malignancy.
In one study, a TEL-AML 1 translocation was de-
tected in 6 of 567 CB samples [9]. Investigators esti-
mate that up to 5% of CB units may contain
preleukemic clones [42]. The use of growth factors
to drive a low number of viable hematopoietic stem
cells also might foster preleukemic mutations, as has
been postulated in patients with aplastic anemia
[8,43,44].
Comparing the incidence of a second myelogenous
malignancy after CB and adult-donor BM or stem cell
transplantation is difficult. In our institution, donor
origin is not routinely tested at the time of suspected
relapse. We believe that the findings of the present
study (which have altered our own practices) should
encourage other investigators to monitor donor origin
for second malignancies after all allogeneic, unrelated,
or CB HSCTs.
Donor-derived second myelogenous malignancies
present unique ethical issues, especially when the
donor is an infant. A consistent system of testing for do-
nor origin in all patients with suspected relapse would
help distinguish relapsed disease from a donor-derived
second malignancy. Should the donor and his or her
parents be notified whenever a donor-derived second
malignancy is diagnosed? Should these donors have
any special follow-up or monitoring? These issues will
need to be addressed as we perform more CBT with
modern technology that allows determination of donor
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